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The type of dietary fat ingested is determined by the fatty acid (FA) composition of foods and nutrition supplements (if consumed) and can substantially influence the human health. It is nowadays considered that the composition of dietary fat is very important in determining health outcomes of metabolic disorders Tvrzicka et al. 2011) . Dietary FA influence their composition in plasma lipoproteins, cell membranes, as well as in adipose tissue (Pedersen et al. 2011) . This tissue has a plethora of endocrine and autocrine/paracrine functions associated with the secretion of adipokines (Virtue & Vidal-Puig 2010) and inflammatory mediators (Browning et al. 2008) . Composition of FA in cell membranes may in turn affect gene expression and metabolism (Flachs et al. 2009 ).
Polyunsaturated FA (PUFA) include the n-6 and n-3 PUFA families. In the n-6 PUFA family the parent FA is linoleic acid (LA). Its metabolic products are g-linolenic (GLA), dihomo-g-linolenic (DHGLA), and arachidonic (AA) acids. High concentrations of n-6 PUFA are found in soybean oil, sunflower seed oil, safflower oil, evening primrose oil, and borage seed oil. As ligands of peroxisome proliferatoractivated receptor-g (PPAR-g), n-6 PUFA increase insulin sensitivity, and change the distribution of fat and the size of adipocytes (Staels 2000) . Importantly, AA is a major precursor of eicosanoids which are potent signalling molecules both inside and outside the cell (Vergroesen 1989) .
In the n-3 PUFA family the parent FA is α-linolenic (ALA). Its main metabolic products are eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. Dietary sources of ALA are seeds and leaves of some plants -soybeans, linseed, blackcurrant seeds and borage leaves. Its metabolites, EPA and DHA, can be taken from the diet through oily fish. (Burdge 2009 ). The immunomodulatory properties of LC n-3 PUFA are related to altered T-lymphocyte activity (Calder 2009 ) and eicosanoid and docosanoid production (Serhan 2011) . In persons with metabolic disorders, FA intake may be inappropriate, characterised by high saturated FA (SFA) and low monounsaturated FA (MUFA) and PUFA intake, especially those of the n-3 PUFA family. Similar changes in plasma FA profiles were found in such diametrically different metabolic disorders as metabolic syndrome (characterised by hypernutrition) on the one side, and different types of malnutrition (marantic type, kwashiorkor-type, cancer cachexia) on the other one. These changes were characterised by significantly decreased content of LA and increased content of palmitoleic acid (Žák et al. 2005, 2007) as well as lower content of plasma n-3 PUFA in cancer patients. Inadequate or inappropriate FA intake may be compensated by nutrition supplements. Furthermore, recent trials have provided strong support for supplementation of n-3 PUFA in patients with cancer. The supplementation of n-3 PUFA resulted in the preservation of fat mass and skeletal muscle during the natural course of cancer cachexia and/or antineoplastic therapy (Murphy et al. 2012) .
The aim of the present study was to analyse the FA composition of nutrition supplements with plant and fish oil extracts, commercially available in the Czech Republic from health food/drug stores or the internet. Information on the FA composition of food supplements should be useful to specialists (physicians, nutritional therapists) as an aid for nutritional recommendations.
MAteriAl ANd MethodS
Supplements analysed. Commercially available nutrition supplements containing plant or fish oils were identified and purchased from health food and drug stores in the Czech Republic during 2005-2011. The supplements are categorised and presented according to their main oil extract: Tables 1-5 . Fatty acid analysis. A sample of 5 μl or 5 mg from each oil supplement (capsule or syrup/tablet) was analysed from one single batch. Samples were converted directly to fatty acid methyl esters (FAME) as previously described (Tvrzicka et al. 2002) and analysed by capillary gas chromatography. 
Soya lecithin
Nutrition supplements with soya lecithin were characterised by a high content of LA (45-60%; Table 6 ). The next most abundant FA were oleic (15-20%) and palmitic acids (14-18%). α-Linolenic acid was present in relatively substantial amounts accounting for 2-8% of total FA. Two supplements (Nos 9 and 15) had a completely different FA profile containing predominately SFA or ΑLA, and they had a low content of LA, possibly related to the content of other ingredients (floral pollen, fermented pollen, Royal jelly, vitamin C, soybean extract, and red clover extract).
evening primrose oil
Evening primrose containing supplements were characterised by a high content of LA (65-75%; Table 7 ), followed by oleic and palmitic acids (both around 6-8%). α-Linolenic acid was found in very low concentrations (0.2-1%), with the exception of one supplement where its content slightly exceeded 2% (No. 28). Borage oil supplements presented in Table 2 had a relatively homogeneous FA profile, containing about 40% LA, followed by oleic and palmitic acids. Total n-6 PUFA levels were around 62% due to the presence of GLA (about 20%). Evening primrose oil supplements also contained a relatively substantial amount of GLA (8-13%).
Amaranth and sea buckthorn oils
Nutrition supplements containing amaranth and sea buckthorn oil had a greatly heterogeneous FA profile as shown in Table 8 . Specifically about amaranth oil supplements, LA varied between 20% and 50% and palmitic acid between 20% and 40%. The content of ALA varied between 0.8% and 4%. The wide range of FA percentages may be explained by the addition of other ingredients to the products concerned (No. 36).
Moreover, sea buckthorn oil supplements followed one of two different patterns. The first pattern had high levels of LA (50%) and a relatively low content of palmitic (15%) and palmitoleic (0.5-11%) acid. The second pattern had a high content of palmitic (35%) and palmitoleic (25-27%) acid and a low content of LA (5%).
Saw palmetto and/or pumpkin seed oils
Non-homogeneous results were also obtained for supplements containing saw palmetto and/or pumpkin seed oils (Table 9 ). Supplements containing saw palmetto (and pumpkin seed) oil greatly varied in their FA profiles. In general terms, saw palmetto oil supplements had a low content of LA (3-6%) and a higher content of oleic (25-40%) and palmitic (8-13%) acid. Saw palmetto oil supplements were dominated by SFA (40-90%); mainly due to high lauric (10-33%) and myristic (5-10%) acid, followed by MUFA and n-6 PUFA. Supplements containing mainly pumpkin seed oil were characterised by a high content of LA (45-55%), followed by oleic (25-35%) and palmitic acid in lower amounts (11%). Supplements which showed a completely different FA profile were Nos 42 and 48.
Fatty acid composition of fish oil containing supplements
A total of 35 fish oil supplements were identified and their FA composition is presented in Table 10 . Most of the fish oil supplements identified did not indicate the origin of the fish oil, although some of them declared whether it was cod or shark liver oil, seal oil, or fish oil of marine origin.
Eicosapentaenoic acid content ranged between 12% and 23% for the majority of the fish oil supplements. However, three supplements had a very high EPA content (60-70%). Only a few supplements had an EPA content of about 5-10% (n = 7) and below 5% (n = 5). As far as DHA is concerned, its content was mainly lower or comparable to EPA, ranging between 7% and 17% in most supplements. There were only a few supplements with DHA ranging between 20% and 30% (n = 6) and between 50% and 60% (n = 2). Also, only a small number of supplements had a DHA content below 5% (n = 5). Three fish oil supplements were identified to have a relatively much higher DHA content compared to EPA (Nos 2, 8, 19) .
diSCuSSioN
Dietary supplements with fish or plant oils are high in PUFA and are often used as a support in the treatment of a number of diseases. Specifically, they are used as a support in body weight and blood lipid management, as well as in metabolic syndrome, because of their pleiotropic effects (Carpentier et al. 2006) . Also, these oils are used in enteral and parenteral nutrition as a supportive treatment of patients in critical care (Novák et al. 2010) .
Soya lecithin and evening primrose oil supplements were the most frequent plant oil supplements. Fatty acids in evening primrose oil supplements originate mainly from triglycerides, and in soya lecithin mainly from phospholipids isolated from soybean oil. Due to its high content of GLA, evening primrose oil is used in diabetic neuropathy and in Δ6-desaturase deficiency (Horrobin 1992) . Essential FA of the n-3 PUFA family, ALA, was found in relatively substantial amounts in soya lecithin.
Importantly, saturated FA were low in most plant oil supplements. Specifically, the lipogenic FA, myristic acid, was low in most of the plant oil supplements. Only saw palmetto oil supplements had a higher SFA content but that was mainly due to having a high lauric acid content rather than myristic acid (Abe et al. 2009 ).
It can be speculated that plant oil supplements which showed a completely different FA profile compared to the expected one either contained plant oils from various plants not declared by the producers, or different parts of the plant and/or different manufacturing procedures were used.
For most of the fish oil supplements there was no indication about the origin or types of fish used. Eicosapentaenoic acid and DHA contents depend primarily on the type of fish whose flesh is used as a source of oil and on the effectiveness of the enrichment technology during manufacturing. Marine fish that feed on phytoplankton have a high content of n-3 PUFA. On the contrary, freshwater fish have a very low content of n-3 PUFA and their oil should not be used for dietary supplements.
For some supplements it is obvious that SFA and MUFA had been partially removed, resulting in the total n-3 PUFA content higher than 66%, even exceeding 90%. These products do not contain any natural fish oil but PUFA ethyl esters from which other FA are removed based on different melting points of particular esters, or re-esterified triacylglycerols. The advantage of LC n-3 PUFA supplements in the form of ethyl esters is that they are manufactured more easily and less expensively compared to triacylglycerols. However, EPA and DHA ethyl ester bioavailability is debatable with recent evidence showing that it might be lower than that of re-esterified triacylglycerols (Neubronner et al. 2011 ).
In conclusion, not all plant and fish oil supplements had a representative FA profile of the main constituent declared. Ideally, FA analysis should be conducted by an independent institution before using an oil supplement for severe health conditions. Each supplement should be considered as a unique product irrespective of its trade name. 
